Literature DB >> 26885142

Pre-operative TNM staging of primary colorectal cancer by (18)F-FDG PET-CT or PET: a meta-analysis including 2283 patients.

Yanwei Ye1, Tao Liu1, Lisha Lu2, Guojun Wang1, Min Wang3, Jingjing Li4, Chao Han5, Jianguo Wen6.   

Abstract

The aim of the present study was to perform a meta-analysis to assess the diagnostic value of fluorine-18 fluorodeoxyglucose ((18)F-FDG) PET-CT/PET in the pre-operative evaluation of TNM staging in patients with primary colorectal cancer (CRC). The Medline, Embase and Web of Knowledge were searched for studies assessing the diagnostic value of (18)F-FDG PET-CT/PET in the pre-operative evaluation of TNM staging in CRC patients. We pooled the sensitivity, specificity, positive and negative Likelihood ratio (LR+ and LR-) and Diagnostic Odds Ratio (DOR) and constructed summary receiver operating characteristic curves. A total of 28 studies including 2283 CRC patients were analyzed. The pre-operative tumor detecting rate of PET-CT was 95.35%, which was superior to CT (P < 0.05). The pooled sensitivity and specificity of pre-operative T staging by PET-CT/PET was 0.73 (95% CI: 0.65-0.81) and 0.99 (95% CI: 0.98-0.99), which the AUC and Q* were 0.96 and 0.91, respectively. Concerning pre-operative N staging, the pooled sensitivity and specificity of PET-CT/PET were 0.62 and 0.70, which the AUC and Q* were 0.76 and 0.70, respectively. As for M staging, the pooled sensitivity and specificity of PET-CT/PET were 0.91 (95% CI: 0.80-0.96) and 0.95 (95% CI: 0.91-0.98), which the AUC and Q* were 0.96 and 0.91, respectively. (18)F-FDG PET-CT/PET had good performance in the pre-operative tumor detecting rate, T staging and M staging in patients with primary CRC, which might alter the therapeutic strategy. However, the diagnostic value of (18)F-FDG PET-CT/PET in pre-operative N staging in CRC patients was not ideal.

Entities:  

Keywords:  18F-FDG-PET; Colorectal cancer; PET-CT; TNM staging; meta-analysis

Year:  2015        PMID: 26885142      PMCID: PMC4723987     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  43 in total

1.  Efficacy of PET/CT in the accurate evaluation of primary colorectal carcinoma.

Authors:  I J Park; H C Kim; C S Yu; M H Ryu; H M Chang; J H Kim; J S Ryu; J S Yeo; J C Kim
Journal:  Eur J Surg Oncol       Date:  2006-07-13       Impact factor: 4.424

2.  18F-FDG PET for evaluation of bone marrow infiltration in staging of lymphoma: a meta-analysis.

Authors:  Emilios E Pakos; Andreas D Fotopoulos; John P A Ioannidis
Journal:  J Nucl Med       Date:  2005-06       Impact factor: 10.057

3.  Positron emission tomography/computed tomography in the staging of colon cancer.

Authors:  Jae Hyung Lee; Min Ro Lee
Journal:  Ann Coloproctol       Date:  2014-02-28

4.  Nodal staging of rectal cancer: high-resolution pelvic MRI versus ¹⁸F-FDGPET/CT.

Authors:  Dae Jung Kim; Joo Hee Kim; Young Hoon Ryu; Tae Joo Jeon; Jeong-Sik Yu; Jae-Joon Chung
Journal:  J Comput Assist Tomogr       Date:  2011 Sep-Oct       Impact factor: 1.826

5.  Combining independent studies of a diagnostic test into a summary ROC curve: data-analytic approaches and some additional considerations.

Authors:  L E Moses; D Shapiro; B Littenberg
Journal:  Stat Med       Date:  1993-07-30       Impact factor: 2.373

6.  Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET: correlation with histopathologic and CT findings.

Authors:  H Abdel-Nabi; R J Doerr; D M Lamonica; V R Cronin; P J Galantowicz; G M Carbone; M B Spaulding
Journal:  Radiology       Date:  1998-03       Impact factor: 11.105

7.  Positron-emission tomography/computed tomography (PET/CT) in the initial staging of primary rectal cancer.

Authors:  T Eglinton; A Luck; D Bartholomeusz; R Varghese; M Lawrence
Journal:  Colorectal Dis       Date:  2009-04-10       Impact factor: 3.788

8.  The impact of 18-fluorodeoxyglucose positron emission tomography-computed tomography on the staging and management of primary rectal cancer.

Authors:  K Davey; A G Heriot; J Mackay; E Drummond; A Hogg; S Ngan; A D Milner; R J Hicks
Journal:  Dis Colon Rectum       Date:  2008-05-07       Impact factor: 4.585

9.  Routine use of positron-emission tomography/computed tomography for staging of primary colorectal cancer: does it affect clinical management?

Authors:  Gokhan Cipe; Nurhan Ergul; Mustafa Hasbahceci; Deniz Firat; Suleyman Bozkurt; Naim Memmi; Oguzhan Karatepe; Mahmut Muslumanoglu
Journal:  World J Surg Oncol       Date:  2013-02-27       Impact factor: 2.754

10.  Positron emission tomography/computed tomography for optimized colon cancer staging and follow up.

Authors:  Bodil Elisabeth Engelmann; Annika Loft; Andreas Kjær; Hans Jørgen Nielsen; Anne Kiil Berthelsen; Tina Binderup; Kim Brinch; Nils Brünner; Thomas Alexander Gerds; Gunilla Høyer-Hansen; Michael Holmsgaard Kristensen; Engin Yeter Kurt; Jan Erik Latocha; Gunnar Lindblom; Carsten Sloth; Liselotte Højgaard
Journal:  Scand J Gastroenterol       Date:  2013-11-29       Impact factor: 2.423

View more
  3 in total

1.  Diagnostic accuracy of FDG-PET/MRI versus pelvic MRI and thoracic and abdominal CT for detecting synchronous distant metastases in rectal cancer patients.

Authors:  Marcelo A Queiroz; Cinthia D Ortega; Felipe R Ferreira; Sergio C Nahas; Giovanni G Cerri; Carlos A Buchpiguel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-06-20       Impact factor: 9.236

2.  Diffuse splenic FDG uptake is predictive of clinical outcomes in patients with rectal cancer.

Authors:  Sang Yoon Kim; Chang Mo Moon; Hai-Jeon Yoon; Bom Sahn Kim; Ji Young Lim; Tae Oh Kim; A Reum Choe; Chung Hyun Tae; Seong-Eun Kim; Hye-Kyung Jung; Ki-Nam Shim; Sung-Ae Jung
Journal:  Sci Rep       Date:  2019-02-04       Impact factor: 4.379

3.  A study of radiomics parameters from dual-energy computed tomography images for lymph node metastasis evaluation in colorectal mucinous adenocarcinoma.

Authors:  Yingying Liu; Yafang Dou; Fang Lu; Lei Liu
Journal:  Medicine (Baltimore)       Date:  2020-03       Impact factor: 1.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.